Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
      Description

      This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy with delayed oophorectomy (ISDO) is surgery to remove the fallopian tubes. It is not known whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the sexual function and psychosocial well-being in patients with genetic mutation.

      Conditions
      Deleterious BARD1 Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationDeleterious BRIP1 Gene MutationDeleterious EPCAM Gene MutationDeleterious MLH1 Gene MutationDeleterious MSH2 Gene MutationDeleterious MSH6 Gene MutationDeleterious PALB2 Gene MutationDeleterious PMS2 Gene MutationDeleterious RAD51C Gene MutationDeleterious RAD51D Gene MutationHereditary Breast and Ovarian Cancer SyndromePremenopausal
      Talk to us
      RECRUITING
      Niraparib, Abiraterone Acetate and Prednisone for MHSPC with Deleterious Homologous Recombination Repair Alterations
      Description

      This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.

      Conditions
      Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene MutationBRCA2 Gene MutationBRIP1 Gene MutationCHEK2 Gene MutationFANCA Gene MutationPALB2 Gene MutationRAD51B Gene MutationRAD54L Gene Mutation
      Talk to us
      TERMINATED
      A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
      Description

      A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.

      Conditions
      Solid Tumor
      Talk to us